Skip to main content
ENTXEntera Bio Ltd.Sell5.4·$3.28
SellModerate Confidence
Investment thesis

Entera Bio is a cash-burning, single-pipeline biotech (EB613) with quality at 1.6/10 and repeated earnings misses; price momentum is positive, but no reliable analyst target exists and little upside is left to the technical target.

Thesis pillars

  • Single Pipeline Concentration↓Deteriorating
  • Cash Burning Low Quality→Stable
  • Widening Earnings Misses→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 8, 2026, based on the 10-K filed Mar 27, 2026

Full reasoning →

Open full analysis

Entera Bio Ltd. (ENTX) Stock Analysis

Inst Constrain edge

SellVALUE-TRAP 1/5QualityModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $3.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 10.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.

Entera Bio Ltd. is a clinical-stage company developing oral tablet peptide and protein replacement therapies via its N-Tab platform, led by EB613 for osteoporosis and EB612 for hypoparathyroidism, plus GLP-1/Glucagon and GLP-2 programs partnered with OPKO Biologics. The company... Read more

$3.28+152.7% A.UpsideScore 5.4/10#89 of 240 Biotechnology
QualityF-score4 / 9FCF yield-2.47%
Stop $3.05Analyst target $8.29(−15% haircut)A.R:R 10.4:1
Analyst consensus$9.75+197.3%4 analysts with price targets
$8.29Analyst target
$3.28price
$9.75mean
$11

Sell if holding. Engine safety override at $3.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 10.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.

Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 130d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.

10-K grounded · weekly refresh

About Entera Bio Ltd.

About Entera Bio Ltd.

Entera Bio's clinical pipeline centers on EB613, an oral once-daily PTH(1-34) tablet for postmenopausal osteoporosis advancing toward a roughly 750-patient Phase 3 study after the FDA's December 2025 qualification of total hip bone mineral density as a surrogate fracture endpoint. The company also develops EB612 for hypoparathyroidism and, with OPKO Biologics, oral GLP-1/Glucagon (EB618) and GLP-2 programs, while reporting no product revenue, an $11.4 million 2025 net loss, and a $125.4 million accumulated deficit.

Entera generates no product revenue today; its business model instead rests on advancing its N-Tab oral-delivery platform, designed to stabilize large hydrophilic peptides against gastrointestinal enzymatic degradation and promote their absorption into the bloodstream, and monetizing that platform through wholly owned and partnered pipeline assets. Entera retains global rights to EB613, its lead osteoporosis candidate, while its hypoparathyroidism, oral GLP-1/Glucagon, and GLP-2 programs run through collaboration and license agreements with OPKO Biologics: the companies split EB612 rights 50/50, and Entera and OPKO split OXM (EB618) proceeds and development costs 40/60, respectively, falling to a 15/85 split if Entera exercises its post-Phase-1 opt-out. The FDA has granted EB612 orphan drug designation, and Entera's most advanced clinical dataset — a Phase 2, 6-month, 161-patient placebo-controlled trial of EB613 — met all biomarker and bone-density endpoints, with results published in the Journal of Bone and Mineral Research in April 2024.

Show full overview

EB613 functions as a binary bet for Entera: the 10-K states existing cash would fund operations only through the middle of the third quarter of 2026, explicitly excluding the costs of starting the Phase 3 osteoporosis trial, and management flagged substantial doubt about the company's ability to continue as a going concern. In July 2026, the company disclosed via Form 8-K a $275.0 million private placement priced at $2.04 per share, addressing that funding gap; because EB613 is Entera's most advanced program and the one to which it retains full global rights (unlike EB612, EB618, and GLP-2, which are shared with OPKO), any delay in Phase 3 execution or an unfavorable readout would disproportionately weigh on the company relative to its partnered assets.

See also: Healthcare · Biotechnology

From Entera Bio Ltd.'s most recent 10-K filing, extracted August 30, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 7, 2026

Recent Developments — Entera Bio Ltd.

Latest item Nov 7, 2026 · Generated 2026-11-20T11:52:16Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Mar 30, 2027130d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Pipeline: EB613
Quality below floor (1.6 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-6.0
Mkt Cap$571M
EV/EBITDA-16.6
Profit Mgn0.0%
ROE-20.3%
Rev Growth—
Beta1.46
DividendNone
Analysts with ratings11

Quality Signals

Piotroski F4/9

Options Flow

P/C0.01bullish
IV262%elevated
Max Pain$2-39.0% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHpipelineEB613
    10-K Item 1A: 'our internal resources are currently focused on the development of EB613 and further development of our N-Tab® platform'

Material Events(8-K, last 90d)

  • 2026-07-28Item 1.01HIGH
    On July 26, 2026, Entera entered a Securities Purchase Agreement for a $275.0 million private placement of ordinary shares and pre-funded warrants to institutional investors including BVF Partners, priced at $2.04/share; closed July 28, 2026, addressing the company's previously disclosed going-concern funding gap.
    SEC filing →
  • 2026-07-16Item 5.02LOW
    At its Annual Meeting, shareholders approved an amendment to Entera's 2018 Equity Incentive Plan increasing the share pool by a one-time 2,500,000 ordinary shares; a routine plan amendment, not an executive departure or appointment.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
4.4
Moat
4.8
Current Ratio
5.0
Cash-burning (FCF negative)No competitive moatQuality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
0.0
Earnings History
1.1
Erm
5.0
Earnings Timing
5.0
Earnings concerns: 1B/2M

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
1.4
Support Resistance
3.0
Gap
5.0
52w Position
5.6
GatesExecutive change: officer departure/appointmentMomentum 6.4>=5.5A.R:R 10.4 ≥ 1.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 130d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
54 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $2.80Resistance $3.49

Price Targets

$3
$8
A.Upside+152.7%
A.R:R10.4:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (1.6 < 4.0)

Earnings

B
M
M
M
1/4 beats
Next Earnings2027-03-30 (130d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ENTX stock a buy right now?

Sell if holding. Engine safety override at $3.28: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 10.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $3.05. Score 5.4/10, moderate confidence.

What is the ENTX stock price target?

Analyst target: $8.29 (+152.7% upside). Prior stop was $3.05. Stop-loss: $3.05.

What are the risks of investing in ENTX?

Concentration risk — Pipeline: EB613; Quality below floor (1.6 < 4.0).

Is ENTX overvalued or undervalued?

Entera Bio Ltd. trades at a P/E of N/A (forward -6.0). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about ENTX?

11 analysts rate ENTX, with a consensus score of 4.3/5. 4 analysts publish price targets averaging $10.

What does Entera Bio Ltd. do?Entera Bio Ltd. is a clinical-stage company developing oral tablet peptide and protein replacement therapies via its...

Entera Bio Ltd. is a clinical-stage company developing oral tablet peptide and protein replacement therapies via its N-Tab platform, led by EB613 for osteoporosis and EB612 for hypoparathyroidism, plus GLP-1/Glucagon and GLP-2 programs partnered with OPKO Biologics. The company has no product revenue, posted an $11.4 million net loss in 2025 on a $125.4 million accumulated deficit, and faces substantial doubt about its ability to continue as a going concern.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I) · MGTX (MeiraGTx Holdings plc) · RIGL (Rigel Pharmaceuticals, Inc.)
Home › Stocks › ENTX

Latest news

Latest News

Fiscal.ai13d ago
Benzinga14d ago
Benzinga21d ago
Benzinga21d ago
Fiscal.ai24d agoLeadership Change
Benzinga38d ago
Benzinga42d ago
Benzinga56d ago
Benzinga59d ago
Benzinga63d ago
Benzinga66d ago
Benzinga77d ago